Shattuck closes up to $103M private placement, appoints two new directors, cash runway into 2029

Shattuck Labs, Inc.

Closed private placement of up to ~$103M led by OrbiMed; net proceeds to fund SL-325 through Phase 2 trials.
Pro forma cash, assuming full warrant exercise, expected to fund operations into 2029.
Appointed Dr. Daniel Baker (independent director) and Dr. Mona Ashiya (OrbiMed designee) to Board.
Directors Tyler Brous, Carrie Brownstein, Michael Lee, Kate Sasser resigned upon closing.
SL-325 (DR3 blocking antibody) IND cleared; Phase 1 trial to start this quarter.

item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.